Status:
COMPLETED
EXtending the tIme Window of Thrombolysis by ButyphThalide up to 6 Hours After Onset (EXIT-BT)
Lead Sponsor:
General Hospital of Shenyang Military Region
Conditions:
Stroke, Ischemic
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
Brief Summary
To date, the time window of intravenous thrombolysis is limited within 4.5 hours of stroke onset. Although EXTEND study has proved that intravenous thrombolysis can be extended from 4.5 to 9 hours, bu...
Eligibility Criteria
Inclusion
- age: 18-80;
- ischemic stroke confirmed by brain CT or MRI
- the time from onset to treatment: 4.5-6 hours
- NIHSS≥4
- prestroke mRS≤1
- signed informed consent
Exclusion
- prestroke mRS≥2
- planned endovascular treatment
- planned intravenous thrombolysis based on WAKE-UP or EXTEND study criterion
- any contraindiction of intravenous thrombolysis
- other unsuitable conditions judged by investigator
Key Trial Info
Start Date :
February 11 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 28 2022
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT05189509
Start Date
February 11 2022
End Date
December 28 2022
Last Update
January 13 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Neurology, General Hospital of Northern Theater Command
Shenyang, China, 110016